Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.CATX · Entity 694 | Chief Financial Officer | September 04, 2025 | September 05, 2025 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Chief Financial Officer | January 02, 2019 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date September 04, 2025 · Filed September 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2035-09-04 | Direct | 600,000 |
Reported balance
After 2025-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-04 · Grant · Acquired 600,000 · Balance 600,000 F1: The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.
Spero Therapeutics, Inc.
Report date January 02, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $6.26 · Expires 2029-01-02 | Direct | 65,000 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 65,000 · Balance 65,000 F1: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2025 Filed Sep 5, 2025 20:06 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 600,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0000950170-25-113245 · ownership.xml · derivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-09-04 F1 · derivative.exercise_date: The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:16 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy · Derivative | 65,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000178 · doc4.xml · derivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019567 · doc4.xml · derivative · entry 3 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,833 Underlying: Common Stock · 2,000 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% on May 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 2,000 | $17.50 | $35,000.00 |
DisclosureSEC source: 0000899243-18-019567 · doc4.xml · nonDerivative · entry 2 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,181 F1 · kind: The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | Exercise / conversionCommon Stock | 2,000 | $5.90 | $11,800.00 |
DisclosureSEC source: 0000899243-18-019567 · doc4.xml · nonDerivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:06 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 27,795 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0000899243-17-028850 · doc4.xml · derivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,795 Underlying: Common Stock · 27,795 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionSeries C Preferred Stock · Derivative | 61,880 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025507 · doc4.xml · derivative · entry 3 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Joel D. Sendek Retained Annuity Trust No. 1 Disclosed balance after: 0 Underlying: Common Stock · 10,181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F1 · derivative.exercise_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F1 · derivative.expiration_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock | 5,000 | $14.00 | $70,000.00 |
DisclosureSEC source: 0000899243-17-025507 · doc4.xml · nonDerivative · entry 2 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,181 F2 · shares: Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionCommon Stock | 10,181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-025507 · doc4.xml · nonDerivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Joel D. Sendek Retained Annuity Trust No. 1 Disclosed balance after: 10,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.